AENA announces the renewal of the management of the existing COVID-19 test centers in 15 Spanish airports, which will be carried out under the Fly COVID Test brand.
ARQUIMEA will manage the largest network of Covid-19 test centers operating at Spanish airports, under the Fly COVID Test brand. It will offer PCR tests, rapid PCR tests, rapid antigen tests, rapid antibody tests and ELISA serological tests.
ARQUIMEA and NSLComm team up to develop BeetleSat, the next generation LEO Backhaul Satellite Constellation. BeetleSat’s non-terrestrial telecom infrastructure will provide satellite operators and global service suppliers with a high-performance LEO satellite telecom layer supplementing their own operations with a ubiquitous, secure, low-latency, cost-effective, multi-gigabyte telecom platform.
Viasat and ARQUIMEA created the G-18L X/Ka antenna — an innovative, dual-band antenna designed specifically to be fitted easily on airborne platforms and communicate with satellites in both X-band and Ka-band frequencies.
ARQUIMEA shared the results of industrialising cameras for the large size telescopes at the Cherenkov Telescope Array (CTA) gamma ray observatory, which is located on the island of La Palma, Canary Islands.
ARQUIMEA attended a new edition of Space Tech Expo 2021 to present the latest innovations in the space sector in the field of rad-hard microelectronics, hi-rel mechanisms and actuators based in Shape Memory Alloys technology and its manufacturing capabilities.
ARQUIMEA, through its Agrotech division, unveils at FIGAN 2021 its automated boar semen analysis systems: ISAS Boar PRO and SQS2. The technology company is focused on developing solutions and products for the farms of the future.
Travel COVID Test centre has been opened at Jerez Airport to provide passengers with their required COVID-19 tests to travel: antigen tests, PCR tests and rapid antibody tests.
ARQUIMEA to supply its HDRM actuators to ClearSpace in the first space mission to ensure the sustainability of space.
The Spanish technology company ARQUIMEA, Ankar Pharma and Circadian Therapeutics have signed an agreement for the co-development of molecules as an innovative treatment for nervous system diseases such as ALS, Parkinson’s or Alzheimer’s disease.